A Comparative Assessment Of Safety, Efficacy, And Cost-Effectiveness Of Glipizide-Metformin And Glimepiride-Metformin Combination Therapy In Type-2 Diabetes Mellitus
DOI:
https://doi.org/10.63682/jns.v14i32S.7461Keywords:
Type 2 Diabetes Mellitus, Glimepiride, Glipizide, Metformin, Combination Therapy, Cost-Effectiveness, Glycaemic Control, Safety, EfficacyAbstract
Background: Type 2 Diabetes Mellitus (T2DM) is a common metabolic syndrome that needs effective long-term glycemic controls. There is wide usage of fixed-dose combinations (FDCs) of metformin with sulfonylureas. Glipizide metformin and glimepiride metformin are among them and these combinations are not effectively compared in terms of clinical and economic outcomes.
Objectives: To compare the safety, efficacy and cost-effectiveness of glipizide metformin and glimepiride metformin fixed dose combination therapy in treating patients with T2DM.
Methods: A prospective comparative study was done over a period of 6 months in a tertiary care hospital in Chennai on 200 T2DM patients. The patients were randomly grouped into Group A (glimepiride 2 mg + metformin 500 mg) and Group B (glipizide 5 mg + metformin 500 mg) and the efficacy was measured by the changes of fasting blood sugar (FBS), postprandial blood sugar (PPBS), random blood sugar (RBS) and HbA1c. The safety was evaluated with the Naranjo causality scale, whereas cost-effectiveness was determined as the cost per cent reduction in glycemic parameters.
Results: Group A showed better glycemic control showing decreases in FBS (36.1%), PPBS (40.2%), RBS (30.1%), and HbA1c (16.8%) than Group B. The adverse drug reactions experienced in both groups were mild and similar. The overall therapy cost was a little higher in Group A but the cost per 1% glycemic reduction was more conducive pointing out to the better cost-effectiveness of the group.
Conclusion: The glimepiride metformin combination therapy is more effective and cost-effective with an equal safety margin and should therefore be the choice of therapy in the long-term management of T2DM.
Downloads
Metrics
References
.World Health Organization. Diabetes - Key facts. Geneva: WHO; 2023.
.American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1): S19-S40.
International Diabetes Federation. IDF Diabetes Atlas, 11th ed. Brussels, Belgium: International Diabetes Federation; 2024. Available from: https://diabetesatlas.org/
Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, et al. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2023;401(10378):1511–1522. doi:10.1016/S0140-6736(23)00301-2Papasoglou E, Moustakas A. Diabetes in Ancient Times: Egypt, Greece and China. Hormones (Athens). 2020;19(4):513-518.
Pickup JC, Williams G. Textbook of Diabetes. 4th ed. Oxford: Blackwell; 2017.
von Mering J, Minkowski O. Diabetes mellitus nach der Extirpation des Pankreas. Arch Exp Pathol Pharmakol. 1890;26:371–387.
Langerhans P. Beiträge zur mikroskopischen Anatomie der Bauchspeicheldrüse. Inaugural Dissertation. Berlin, 1869.
Banting FG, Best CH, Collip JB, Macleod J, Campbell WR. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12(3):141–146.
Bliss M. The Discovery of Insulin. University of Chicago Press; 1982.
. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579.
Starzl TE, Lillehei RC, Najarian JS, et al. Homotransplantation of the pancreas and duodenum along with the kidney. Surg Gynecol Obstet. 1967;124(4):991-999.
. Clarke SF, Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012;69(2):83-93.
. Johnson IS, et al. Human insulin from recombinant DNA technology. Science. 1983;219(4585):632-637.
. Bergenstal RM, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224-232.
. Shapiro AMJ, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230-238.
. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19-39.
Birabaharan M, Kaelber DC, Pettus JH, Smith DM. Risk of new-onset type 2 diabetes in 600,055 people after COVID‑19: Diabetes Obes Metab. 2022;24(6):1176–1179.
. Weill Cornell Medicine–Qatar et al. Systematic review of 35 studies: 4.4 million patients, 60,189 new-onset diabetes (1.37%). Emerg Microbes Infect. 2025.
. Lancet eBioMedicine cohort: 16.7% hospitalized COVID-19 vs 12% influenza³.
. Zhang T, et al. Meta-analysis: 5% incidence (95% CI 2–10%) of new-onset diabetes or hyperglycemia post-COVID‑19. Front Public Health. 2023.
Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799-806.
. Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012;367(14):1332-1340.
. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69‑82.
. Maahs DM, West NA, Lawrence JM, Mayer‑Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481‑497.
Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016;387(10035):2331‑2339.
DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335‑1343.
Fonseca VA, Efendic S, Falahati A, Hollander P. Addition of glipizide to metformin therapy improves glycaemic control in type 2 diabetes. Clin Ther. 2000;22(10):1182‑1190.
. American Diabetes Association. Pharmacologic approaches to glycaemic treatment: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S125‑S143.
. Schwartz SL, Sievers R, Strange P, Lyness WH, Hollander P. Efficacy and safety of glimepiride‑metformin tablets in type 2 diabetes mellitus. Clin Ther. 2003;25(3):799‑807.
Rodbard HW, Jellinger PS, Davidson JA, et al. Optimization of insulin therapy in patients with type 2 diabetes mellitus. Endocr Pract. 2022;28(3):260‑292.
Davidson JA, Peters AL. "Clinical use of sulfonylureas in type 2 diabetes mellitus: balancing the benefits and risks." Curr Diab Rep. 2004;4(5):387–393.
Schernthaner G, Grimaldi A, Di Mario U, et al. "GUIDE study: double-blind comparison of once-daily Glimepiride and twice-daily Glipizide in type 2 diabetic patients." Diabetes Res Clin Pract. 2004;65(2):77–85.
Marre M, Howlett H, Lehert P, et al. "Efficacy and safety of Glimepiride versus Glipizide in Type 2 diabetes: a meta-analysis." Clin Ther. 2002;24(5):841–857.
DeFronzo RA, Goodman AM. "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med. 1995;333(9):541–549.
Kaku K, Kiyosue A, Ono Y, Shiraiwa T. "Cost-effectiveness of Glimepiride compared with Glipizide in patients with type 2 diabetes mellitus." J Diabetes Investig. 2013;4(1):52–59.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
